Veloxis Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on therapies for organ transplantation, particularly immunosuppressive treatments used to prevent rejection in kidney and liver transplant recipients. The company engages in the development and commercialization of transplant-focused medicines.
Veloxis is known for marketing once-daily, extended-release tacrolimus in the United States under the Envarsus XR brand. The company operates as a wholly owned subsidiary of Asahi Kasei Group, following its acquisition in 2020, and collaborates across clinical development and commercialization to expand options in transplant medicine.
